Beta-blockers and Statins: Role in Portal Hypertension and Beyond

Fabio Heleno de Lima Pace, Helena Maria Giordano Valério, Juliano Machado de Oliveira, Kátia Valéria Bastos Dias Barbosa, Tarsila Campanha da Rocha Ribeiro, Julio Maria Fonseca Chebli


Clinically significant portal hypertension is a cornerstone in cirrhosis’s natural history, significantly impacting these patients’ morbidity and mortality. Unless adequate preventive measures are implemented, the recurrence rate of bleeding can reach up to 65% of patients and with mortality of 57%. The goals in portal hypertension treatment focus on reducing the hepatic venous portal gradient, both by reducing portal blood flow and intrahepatic resistance. Nonselective beta-blockers and esophageal varices ligation have been the standard of care in esophageal varices’ treatment. Currently, statins and carvedilol’s role in reducing portal pressure, preventing esophageal variceal bleeding, and other advanced liver disease complications seem to be promising.


Portal hypertension; Variceal bleeding; Nonselective beta-blockers; Carvedilol; Statins

Full Text: PDF HTML


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.